This study reveals that Fc-enhanced anti-CTLA-4 harnesses novel mechanisms to overcome the limitations of conventional anti-CTLA-4, effectively treating poorly immunogenic and treatment-refractory cancers. Our findings support the development of a new class of immuno-oncology agents, capable of extending clinical benefit to patients with cancers resistant to current immunotherapies.
Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy.
Botensilimab 是一种 Fc 增强型抗 CTLA-4 抗体，对传统免疫疗法反应不佳的肿瘤有效
阅读：5
作者：Chand Dhan, Savitsky David A, Krishnan Shanmugarajan, Mednick Gabriel, Delepine Chloe, Garcia-Broncano Pilar, Soh Kah Teong, Wu Wei, Wilkens Margaret K, Udartseva Olga, Vincent Sylvia, Joshi Bishnu, Keith Justin G, Manrique Mariana, Marques Marilyn, Tanne Antoine, Levey Daniel L, Han Haiyong, Ng Serina, Ridpath Jackson, Huber Olivia, Morin Benjamin, Galand Claire, Bourdelais Sean, Gombos Randi B, Ward Rebecca, Qin Yu, Waight Jeremy D, Costa Matthew R, Sebastian-Yague Alvaro, Rudqvist Nils-Petter, Pupecka-Swider Malgorzata, Venkatraman Vignesh, Slee Andrew, Patel Jaymin M, Grossman Joseph E, Wilson Nicholas S, Von Hoff Daniel D, Stebbing Justin, Curiel Tyler J, Buell Jennifer S, O'Day Steven J, Stein Robert B
| 期刊： | Cancer Discovery | 影响因子： | 33.300 |
| 时间： | 2024 | 起止号： | 2024 Dec 2; 14(12):2407-2429 |
| doi： | 10.1158/2159-8290.CD-24-0190 | 研究方向： | 肿瘤 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。
2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。
4、投稿及合作请联系：info@biocloudy.com。